Thomas Flaten
Stock Analyst at Lake Street
(1.94)
# 2,824
Out of 5,182 analysts
43
Total ratings
33.33%
Success rate
-2.27%
Average return
Main Sectors:
Stocks Rated by Thomas Flaten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASRT Assertio Holdings | Downgrades: Hold | $45 → $18 | $18.04 | -0.22% | 4 | Apr 9, 2026 | |
| EVAX Evaxion | Maintains: Buy | $11 → $9 | $4.32 | +108.33% | 4 | Mar 9, 2026 | |
| IMDX Insight Molecular Diagnostics | Maintains: Buy | $8 → $12 | $4.20 | +185.71% | 1 | Feb 17, 2026 | |
| CSTL Castle Biosciences | Maintains: Buy | $35 → $52 | $24.69 | +110.61% | 7 | Jan 12, 2026 | |
| PTHS Pelthos Therapeutics | Initiates: Buy | $50 | $24.97 | +100.24% | 1 | Dec 3, 2025 | |
| CNTB Connect Biopharma Holdings | Initiates: Buy | $9 | $2.40 | +275.00% | 1 | Dec 1, 2025 | |
| MDXH MDxHealth | Maintains: Buy | $7 → $9 | $2.04 | +341.18% | 1 | Nov 13, 2025 | |
| HROW Harrow | Maintains: Buy | $42 → $70 | $40.48 | +72.92% | 1 | Sep 29, 2025 | |
| DERM Journey Medical | Maintains: Buy | $9 → $13 | $5.26 | +147.15% | 2 | Aug 13, 2025 | |
| RPID Rapid Micro Biosystems | Initiates: Buy | $8 | $2.46 | +225.20% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $14 | $6.22 | +125.08% | 2 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.55 | +213.73% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $40 | $9.95 | +302.01% | 1 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $17 → $9 | $9.60 | -6.25% | 5 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $4.09 | +95.60% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $5.50 | +63.64% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $11 | $4.27 | +157.61% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $25 | $20.90 | +19.62% | 2 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14,400 → $1,440 | $0.38 | +375,977.30% | 2 | Nov 17, 2022 |
Assertio Holdings
Apr 9, 2026
Downgrades: Hold
Price Target: $45 → $18
Current: $18.04
Upside: -0.22%
Evaxion
Mar 9, 2026
Maintains: Buy
Price Target: $11 → $9
Current: $4.32
Upside: +108.33%
Insight Molecular Diagnostics
Feb 17, 2026
Maintains: Buy
Price Target: $8 → $12
Current: $4.20
Upside: +185.71%
Castle Biosciences
Jan 12, 2026
Maintains: Buy
Price Target: $35 → $52
Current: $24.69
Upside: +110.61%
Pelthos Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $50
Current: $24.97
Upside: +100.24%
Connect Biopharma Holdings
Dec 1, 2025
Initiates: Buy
Price Target: $9
Current: $2.40
Upside: +275.00%
MDxHealth
Nov 13, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $2.04
Upside: +341.18%
Harrow
Sep 29, 2025
Maintains: Buy
Price Target: $42 → $70
Current: $40.48
Upside: +72.92%
Journey Medical
Aug 13, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $5.26
Upside: +147.15%
Rapid Micro Biosystems
Jul 28, 2025
Initiates: Buy
Price Target: $8
Current: $2.46
Upside: +225.20%
Jul 18, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $6.22
Upside: +125.08%
Jul 1, 2025
Initiates: Buy
Price Target: $8
Current: $2.55
Upside: +213.73%
May 14, 2025
Maintains: Buy
Price Target: $60 → $40
Current: $9.95
Upside: +302.01%
Mar 20, 2025
Downgrades: Hold
Price Target: $17 → $9
Current: $9.60
Upside: -6.25%
Mar 7, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $4.09
Upside: +95.60%
Jan 8, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $5.50
Upside: +63.64%
Mar 5, 2024
Maintains: Buy
Price Target: $19 → $11
Current: $4.27
Upside: +157.61%
Aug 9, 2023
Maintains: Buy
Price Target: $34 → $25
Current: $20.90
Upside: +19.62%
Nov 17, 2022
Maintains: Buy
Price Target: $14,400 → $1,440
Current: $0.38
Upside: +375,977.30%